NDA 020922 · Almirall
Solage
Mequinol, Tretinoin · Topical
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 2, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Dec 10, 1999
Approved uses
2
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 25, 2007 Supplement 3 · Efficacy LabelLetter
- Dec 10, 1999 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination LetterLabelReview
1 products under this application
- SOLAGE · MEQUINOL 2%; TRETINOIN 0.01% · SOLUTION, TOPICAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Mequinol" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of Solar Lentigines: A Systematic Review of Clinical Trials.
Mardani G, Nasiri MJ, Namazi N, et al. · J Cosmet Dermatol 2025 · Systematic Review
- Analytic quantification of the bleaching effect of a 4-hydroxyanisole-tretinoin combination on actinic lentigines.
Piérard-Franchimont C, Henry F, Quatresooz P, et al. · J Drugs Dermatol 2008 · Randomized Controlled Trial
- Safety and efficacy of combined use of 4-hydroxyanisole (mequinol) 2%/tretinoin 0.01% solution and sunscreen in solar lentigines.
Ortonne JP, Camacho F, Wainwright N, et al. · Cutis 2004 · Clinical Trial, Multicenter Study
- The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies.
Fleischer AB, Schwartzel EH, Colby SI, et al. · J Am Acad Dermatol 2000 · Clinical Trial, Clinical Trial, Phase III
- Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines.
Jarratt M · Cutis 2004 · Clinical Trial, Randomized Controlled Trial
- The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups.
Draelos ZD · J Cosmet Dermatol 2006 · Clinical Trial
Sponsor: Almirall
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.